Cytochrome P450 in Cancer Susceptibility and Treatment

被引：88

作者：

Mittal, Balraj ^{[1
]}

Tulsyan, Sonam ^{[1
]}

Kumar, Surendra ^{[1
]}

Mittal, Rama Devi ^{[2
]}

Agarwal, Gaurav ^{[3
]}

机构：

[1] Sanjay Gandhi Post Grad Inst Med Sci, Dept Genet, Lucknow, Uttar Pradesh, India

[2] Sanjay Gandhi Post Grad Inst Med Sci, Dept Urol & Renal Transplant, Lucknow, Uttar Pradesh, India

[3] Sanjay Gandhi Post Grad Inst Med Sci, Dept Endocrine Surg, Lucknow, Uttar Pradesh, India

来源：

ADVANCES IN CLINICAL CHEMISTRY, VOL 71 | 2015年 / 71卷

关键词：

SQUAMOUS-CELL CARCINOMA; GLUTATHIONE-S-TRANSFERASE; HUMAN LIVER-MICROSOMES; GASTROINTESTINAL STROMAL TUMORS; ACUTE LYMPHOBLASTIC-LEUKEMIA; NORTH INDIAN POPULATION; POSITIVE BREAST-CANCER; RIO-DE-JANEIRO; PHASE-II TRIAL; METABOLIZING ENZYME POLYMORPHISMS;

D O I：

10.1016/bs.acc.2015.06.003

中图分类号：

R446 [实验室诊断]; R-33 [实验医学、医学实验];

学科分类号：

1001 ;

摘要：

Cytochrome 450 (CYP450) designates a group of enzymes abundant in smooth endoplasmic reticulum of hepatocytes and epithelial cells of small intestines. The main function of CYP450 is oxidative catalysis of various endogenous and exogenous substances. CYP450 are implicated in phase I metabolism of 80% of drugs currently in use, including anticancer drugs. They are also involved in synthesis of various hormones and influence hormone-related cancers. CYP450 genes are highly polymorphic and their variants play an important role in cancer risk and treatment. Association studies and meta-analyses have been performed to decipher the role of CYP450 polymorphisms in cancer susceptibility. Cancer treatment involves multimodal therapies and evaluation of CYP450 polymorphisms is necessary for pharmacogenetic assessment of anticancer therapy outcomes. In addition, CYP450 inhibitors are being evaluated for improved pharmacokinetics and oral formulation of several anticancer drugs.

引用

页码：77 / 139

页数：63

共 50 条

[41] Cytochrome P450 CYP1A1 MspI polymorphism and lung cancer susceptibility
Xu, XP
Kelsey, KT
Wiencke, JK
Wain, JC
Christiani, DC
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 1996, 5 (09) : 687 - 692
[42] Cytochrome P450 - Preface
Lu, AYH
CURRENT DRUG METABOLISM, 2001, 2 (02) : U4 - U4
[43] Cytochrome P450 engineering
Pompon, Denis
Truan, Gilles
Urban, Philippe
BIOFUTUR, 2008, (288) : 34 - 38
[44] Preface: Cytochrome P450
Plettner, Erika
BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS, 2018, 1866 (01): : 1 - 1
[45] Genetic polymorphism of cytochrome P450 as a biomarker of susceptibility to environmental toxicity
Hong, JY
Yang, CS
ENVIRONMENTAL HEALTH PERSPECTIVES, 1997, 105 : 759 - 762
[46] Structure of Cytochrome P450 Reductase in an Open Conformation Capable of Reducing Cytochrome P450
Waskell, Lucy
Kim, Jung-Ja P.
Hamdane, Djemel
Xia, Chuanwu
Im, Sang-Choul
Zhang, Haoming
FASEB JOURNAL, 2009, 23
[47] A Minimal Functional Complex of Cytochrome P450 and FBD of Cytochrome P450 Reductase in Nanodiscs
Prade, Elke
Mahajan, Mukesh
Im, Sang-Choul
Zhang, Meng
Gentry, Katherine A.
Anantharamaiah, G. M.
Waskell, Lucy
Ramamoorthy, Ayyalusamy
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION, 2018, 57 (28) : 8458 - 8462
[48] Modeling of cytochrome P450 (Cyt P450, CYP) channels
Jankowski, Christopher K.
Chiasson, Julien B.
Dako, Etienne
Doucet, Kathy
Surette, Marc E.
Andre, Francois
Delaforge, Marcel
SPECTROSCOPY-BIOMEDICAL APPLICATIONS, 2011, 25 (02): : 63 - 87
[49] Probing the Role of the Hinge Segment of Cytochrome P450 Oxidoreductase in the Interaction with Cytochrome P450
Campelo, Diana
Esteves, Francisco
Palma, Bernardo Brito
Gomes, Bruno Costa
Rueff, Jose
Lautier, Thomas
Urban, Philippe
Truan, Gilles
Kranendonk, Michel
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2018, 19 (12)
[50] Cytochrome P450 recognition sites for NADPH cytochrome P450 reductase and substrates.
Dai, R
Robinson, RC
Friedman, FK
BIOPHYSICAL JOURNAL, 1997, 72 (02) : MP290 - MP290

← 1 2 3 4 5 →